| The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to just a few months. This experience raises a tantalising question: can such speed be sustained for other treatments?
To help answer the question, Merck KGaA, Darmstadt, Germany MilliporeSigma sponsored a report by Economist Impact exploring how stakeholders were able to move so quickly during a global crisis. The main takeaways: policy choices that sustain global bio-manufacturing networks, regulatory streamlining, supply chain resilience, technical support, data science to anticipate and manage supply chain risks, and the many changes in process applied during the pandemic that could aid the development of future medicines, especially with the help of advanced manufacturing.
So important that governments and Geneva negotiators implement R&D and regulatory policies that facilitate public-private collaboration, technology uptake, and bio-infrastructure development. Learn more now!
Thanks to Jennifer Brant, Oliver A. Prince, Ph.D., Anissa Boumlic-Courtade for the original research; and to Brendan O’Sullivan, Kevin Lardner, Joseph Letterman, Godfrey Firth and Jim Neville for contributing to the analysis. #vaccines #biologics #manufacturing #localization #publicprivatepartnership #techtransfer #investment |
Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape
by Carole Inglevert |
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert/
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert/
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert/
-
Carole Ingleverthttps://emergingbiotalk.com/author/carole-inglevert/
Related Posts
Emerging Biotech · Gene Therapy
Starting your journey into manufacturing – choosing a cell line development provider
One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …
by Dr. Jonathan H. Dempsey
Vaccines
Covid-19 Impact on Bioprocessing: PART 1 Accelerating Trends
The views and opinions expressed in this blog / article are those of the authors and do not…
by Eric Langer, Ronald Rader and Kamna Jhamb
Vaccines
Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid-19
The views and opinions expressed in this blog / article are those of the authors and do not…
by Ronald Rader, Kamna Jhamb and Eric Langer
Vaccines
Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic
The views and opinions expressed in this blog / article are those of the authors and do not…
